Cyld | CYLD lysine 63 deubiquitinase
Physiological systems
16 / 24 physiological systems tested
3 Significantly impacted by the knock-out
Immune system Hematopoietic system Behavior/neurological
13 No significant impact
8 Not tested
Data collections
Gene metrics:5Significant phenotypes
6Associated diseases
Expression examined in:0Adult tissues
0Embryo tissues
| decreased locomotor activity | 8 supporting datasets | Cyldem2(IMPC)Marc | homozygote | Early adult | 1.43x10-11 | ||
| increased basophil cell number | 2 supporting datasets | Cyldem2(IMPC)Marc | homozygote | Early adult | 1.96x10-35 | ||
| decreased exploration in new environment | 1 supporting dataset | Cyldem2(IMPC)Marc | homozygote | Early adult | 8.32x10-6 | ||
| increased grip strength | 1 supporting dataset | Cyldem2(IMPC)Marc | homozygote | Early adult | 5.97x10-9 | ||
| increased eosinophil cell number | 2 supporting datasets | Cyldem2(IMPC)Marc | homozygote | Early adult | 1.35x10-12 |
| | | | | | | | | | |
Human diseases caused by Cyld mutations
The analysis uses data from IMPC, along with published data on other mouse mutants, in comparison to human disease reports in OMIM, Orphanet, and DECIPHER.
Phenotype comparisons summarize the similarity of mouse phenotypes with human disease phenotypes.
External links
No external links available for Cyld.
All available products are supplied via our member's centres or partnerships. When ordering a product from the IMPC you will be redirected to one of their websites or prompted to start an email.